Adding an anti-inflammatory drug to anti-PD1 checkpoint inhibitor immunotherapy has shown great promise as a new strategy against advanced lung cancer, based on results from a small clinical trial led by investigators at the Abramson Family Cancer Center at the University of Pennsylvania Perelman School of Medicine.
Deka Biosciences secures $20m to advance product pipeline
The company will use the funding proceeds to progress its pipeline and the production of drug products. Credit: Matveev Aleksandr/Shutterstock.com. Deka Biosciences has secured funding of
September 29, 2023